Teaching hospital Program year 2025 Source: CMS Open Payments

Massachusetts General Hospital

MA

CCN 220071 CMS hospital 16226

Open in the dashboard

General payments

$418,682,079

2,813 payments

Research payments

$343,858,076

14,595 payments

Through program year 2025, Massachusetts General Hospital is reported as receiving $418,682,079 in general payments and $343,858,076 in research payments from drug and medical device manufacturers.

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $12,936,279 243
2025 Research $46,226,137 2,376
2024 General $40,023,757 611
2024 Research $51,526,267 2,315
2023 General $40,735,598 289
2023 Research $48,691,276 2,093
2022 General $45,808,910 618
2022 Research $49,503,292 1,701
2021 General $45,598,087 311
2021 Research $53,439,771 2,172
2020 General $9,420,871 391
2020 Research $47,939,537 1,894
2019 General $224,158,576 350
2019 Research $46,531,796 2,044

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $215,140,537 85 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $118,760,892 47 payments
  3. Illumina, Inc. $12,771,913 10 payments
  4. Stryker Corporation $11,253,155 62 payments
  5. Beckman Coulter, Inc. $7,934,456 14 payments
  6. Ge Healthcare $6,925,554 97 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $3,688,558 10 payments
  8. AbbVie, Inc. $2,590,132 12 payments
  9. AstraZeneca Pharmaceuticals LP $2,573,713 21 payments
  10. OMNIlife science, Inc $2,419,387 26 payments
  11. Other $34,623,784 2,429 payments
What the payments were for General payments · program years 2019–2025
  1. Royalty or License $385,276,476 889 payments
  2. Consulting Fee $11,263,544 175 payments
  3. Grant $10,462,887 288 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,606,150 508 payments
  5. Space rental or facility fees (teaching hospital only) $1,228,048 109 payments
  6. Education $1,161,192 116 payments
  7. Charitable Contribution $1,057,774 45 payments
  8. Long term medical supply or device loan $724,158 131 payments
  9. Gift $585,390 106 payments
  10. Debt forgiveness $308,836 437 payments
  11. Other $7,625 9 payments
Products named General payments · program years 2019–2025
  1. IT VitE XLPE Liners $204,176,412 4 payments
  2. E1 $199,635,892 3 payments
  3. Entyvio $118,037,425 9 payments
  4. Reproductive Health $12,771,913 10 payments
  5. Mako $9,612,593 21 payments
  6. Unicel Dxi Access Devices $3,383,611 5 payments
  7. Access 2 Devices $3,383,611 5 payments
  8. Unicel Dxi Access Immunoassay $2,864,821 8 payments
  9. Access 2 Immunoassay $2,864,821 8 payments
  10. IT XLPE Liners $2,238,467 11 payments
  11. Other $28,253,881 1,088 payments

A payment can name more than one product, so these amounts overlap.

2,813 general · 14,595 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

A teaching hospital's total is institutional. It is money reported as going to the hospital itself, and it is kept separate from anything reported about the individual clinicians who work there — the two are never added together.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record